Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events
Sign Up to like & getrecommendations! Published in 2019 at "JAMA Cardiology"
DOI: 10.1001/jamacardio.2018.4566
Abstract: Importance In the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial, the anti-inflammatory monoclonal antibody canakinumab significantly reduced the risk of recurrent cardiovascular events in patients with previous myocardial infarction (MI) and high-sensitivity C-reactive protein (hs-CRP)… read more here.
Keywords: cost effectiveness; recurrent cardiovascular; canakinumab; cardiovascular events ... See more keywords
Location of recurrent cardiovascular events and anticardiolipin antibodies
Sign Up to like & getrecommendations! Published in 2021 at "European Journal of Clinical Investigation"
DOI: 10.1111/eci.13533
Abstract: The relationship between anticardiolipin (aCL) antibodies and cardiovascular events is uncertain and may vary according to arterial location. read more here.
Keywords: location; location recurrent; recurrent cardiovascular; anticardiolipin antibodies ... See more keywords
Respiratory Polygraphy Patterns and Risk of Recurrent Cardiovascular Events in Patients With Acute Coronary Syndrome
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2022.870906
Abstract: Introduction Obstructive sleep apnea (OSA) severity is based on the apnea-hypopnea index (AHI). The AHI is a simplistic measure that is inadequate for capturing disease severity and its consequences in cardiovascular diseases (CVDs). Deleterious effects… read more here.
Keywords: events patients; component; recurrent cardiovascular; risk recurrent ... See more keywords